Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum ABSWOBY -6.00%67 Debt-to-EBITDA is 1.32 as of Jun. 2026, which is 26% below its 10-year median of 1.79. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $18.40 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 689 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 54.72% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's Debt-to-EBITDA or its related term are showing as below:
SWOBY'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 1.79 Max: 2.82
Current: 1.38
During the past 13 years, the highest Debt-to-EBITDA Ratio of Swedish Orphan Biovitrum AB was 2.82. The lowest was 0.00. And the median was 1.79.
SWOBY's Debt-to-EBITDA is ranked better than 54.72% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs SWOBY: 1.38
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Swedish Orphan Biovitrum AB Debt-to-EBITDA Related Terms
Swedish Orphan Biovitrum AB Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Swedish Orphan Biovitrum AB (SWOBY) has a Debt-to-EBITDA of 1.32 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Swedish Orphan Biovitrum AB. This is 26% below median its historical median of 1.79. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #312 out of 689 companies in the Drug Manufacturers industry, placing it in the top 45.3%.
Is Swedish Orphan Biovitrum AB's Debt-to-EBITDA too high?
Swedish Orphan Biovitrum AB's current Debt-to-EBITDA of 1.32 is 26% below median its 10-year median of 1.79. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Swedish Orphan Biovitrum AB's value of 1.32 is 19.5% below this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #312 out of 689 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #312 out of 689 companies for Debt-to-EBITDA. This puts Swedish Orphan Biovitrum AB in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. Swedish Orphan Biovitrum AB's value of 1.32 is 19.5% below this benchmark. While the company's 10-year median is 1.79 vs. the industry median of 1.64, Swedish Orphan Biovitrum AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Debt-to-EBITDA of 1.32 is 19.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Swedish Orphan Biovitrum AB. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Debt-to-EBITDA is 1.32, which is 26% below median its own 10-year median of 1.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Modestly Overvalued. The stock's GF Value™ is $18.40, compared to a current price of $23.50 — trading 27.7% above its estimated fair value. The current Debt-to-EBITDA is 1.32, which is 26% below median its 10-year median of 1.79 and 19.5% below the Drug Manufacturers industry median of 1.64. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Debt-to-EBITDA is 1.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.50 is trading 27.7% above its estimated GF Value™ of $18.40.
GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.
Key valuation signals for SWOBY:
Debt-to-EBITDA: 1.32 (26% below median its 10-year median of 1.79)
GF Value™: $18.40 vs. price of $23.50 (27.7% above fair value)
Industry Position: 19.5% below the Drug Manufacturers median (#312 of 689)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
